SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Lazard Asset Management LLC

Lazard Asset Management LLC increased its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 50.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,839 shares of the company's stock after purchasing an additional 23,015 shares during the period. Lazard Asset Management LLC owned 0.16% of SI-BONE worth $965,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in SIBN. American Century Companies Inc. lifted its stake in shares of SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock worth $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of SI-BONE by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after buying an additional 9,847 shares during the period. Impax Asset Management Group plc lifted its position in SI-BONE by 1.1% during the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock worth $10,750,000 after acquiring an additional 8,240 shares in the last quarter. Pier Capital LLC boosted its holdings in SI-BONE by 1.6% in the 4th quarter. Pier Capital LLC now owns 473,123 shares of the company's stock worth $6,633,000 after acquiring an additional 7,225 shares during the period. Finally, Northern Trust Corp grew its position in SI-BONE by 6.3% in the fourth quarter. Northern Trust Corp now owns 409,122 shares of the company's stock valued at $5,736,000 after acquiring an additional 24,214 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial raised their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,424 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $19.48, for a total transaction of $47,219.52. Following the sale, the chief financial officer now directly owns 222,083 shares of the company's stock, valued at approximately $4,326,176.84. This represents a 1.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. This trade represents a 1.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,565 shares of company stock worth $1,669,871 over the last quarter. 4.00% of the stock is owned by corporate insiders.

SI-BONE Stock Down 0.2%

Shares of NASDAQ:SIBN traded down $0.04 during midday trading on Monday, reaching $18.38. The company had a trading volume of 273,310 shares, compared to its average volume of 375,257. The stock has a market capitalization of $783.26 million, a P/E ratio of -19.98 and a beta of 0.82. The stock's fifty day moving average price is $15.30 and its 200-day moving average price is $15.21. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Equities research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.